

Rev03
 Update: Aug,08,2025

DATASHEET

PADI4, His, Cynomolgus

Cat. No.: Z04890

Product Introduction

Species	Cynomolgus
Protein Construction	<div style="display: flex; align-items: center; justify-content: center;"> <div style="background-color: #4a7c9c; color: white; padding: 5px; margin-right: 10px;">His</div> <div style="background-color: #0070c0; color: white; padding: 5px; border: 1px solid white;"> PADI4 (Met1-Pro663) Accession # A0A2K5USI5 </div> </div> <div style="display: flex; justify-content: space-around; margin-top: 5px;"> N-term C-term </div>
Purity	> 95% as determined by Bis-Tris PAGE
Endotoxin Level	Less than 1EU per µg by the LAL method.
Expression System	E.coli
Theoretical Molecular Weight	76.6 kDa
Apparent Molecular Weight	The protein has a predicted MW of 76.6 kDa same as Bis-Tris PAGE result.
Formulation	Supplied as 0.22µm filtered solution in 20mM Tris, 500mM NaCl, 10% Glycerol, 0.5mM TCEP, 1mM EDTA (pH 8.0).
Concentration	Verified by one or more methods from A280/Bioactivity/BCA/Bradford.
Storage & Stability	This product remains stable for 6 months at -80°C or below. Avoid repeated freeze-thaw cycles.

Background

Target Background : Peptidylarginine deiminase type4 (PADI4) was firstly identified as a non-MHC RA genetic risk factor. Furthermore, PADI4 risk allele possessed the association with bone damage regardless of anti citrullinated peptide antibody (ACPA) positivity in Asian RA patients. PADI4 gene codes PAD4 protein which has post-translational modification activity (citrullination). Padi4 is mainly expressed in myeloid cells and granulocytes.

Synonyms : Protein-arginine deiminase type-4; HL-60 PAD; HL60 PAD; HL-60; PAD; PAD4; PADI5; PDI5

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.

Manufacturer: Nanjing GenScript Biotech Co., Ltd. No. 28Yongxi Road, Jiangning District, Nanjing, Jiangsu, China